Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +1.85% 27.50p 26.00p 29.00p 27.50p 27.00p 27.00p 46,113.00 15:28:38
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -2.6 -2.5 - 25.12

Synairgen (SNG) Latest News

More Synairgen News
Synairgen Takeover Rumours

Synairgen (SNG) Share Charts

1 Year Synairgen Chart

1 Year Synairgen Chart

1 Month Synairgen Chart

1 Month Synairgen Chart

Intraday Synairgen Chart

Intraday Synairgen Chart

Synairgen (SNG) Discussions and Chat

Synairgen Forums and Chat

Date Time Title Posts
17/2/201709:35Synairgen - a cure for Asthma?522.00
19/10/201007:22Synairgen - Blockbusting potential50.00
17/3/201018:34Canadian Superior Energy: No.American Gas&Oil8.00

Add a New Thread

Synairgen (SNG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
20/02/2017 15:22:5128.001,203336.84O
20/02/2017 15:02:4128.002,279638.12O
20/02/2017 15:01:1326.552,492661.63O
20/02/2017 12:12:3227.993,5751,000.64O
20/02/2017 12:07:0328.0020,0005,600.00O
View all Synairgen trades in real-time

Synairgen (SNG) Top Chat Posts

Synairgen Daily Update: Synairgen Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 27p.
Synairgen Plc has a 4 week average price of 21.22p and a 12 week average price of 17.17p.
The 1 year high share price is 38p while the 1 year low share price is currently 12.50p.
There are currently 91,362,612 shares in issue and the average daily traded volume is 590,129 shares. The market capitalisation of Synairgen Plc is £25,124,718.30.
wookie77: technically I would expect the share price to target 25p where next resistance is.
wookie77: Thanks Ohisay........If SNG share price can get above the 40p neck line then we really are off to the races IMO.
wookie77: I wonder if the cats out of the bag now with regard to the huge potential here. Amazing strength in share price and a proper break out on the cards here. I'm sure quite a few are aware of the maturing Astra Zenaca trials and givin liquidity issues are anxious not to leave it too late for fear of missing out. This is similar potential if not great to GWP and look at how amazing that has been especially those who bought at the bottom. That's a retirement fund right there!
wookie77: Really interesting share price action recently. Could the bottom now be in and we now begin our long awaited rerating up to AZN results
wookie77: Yeah. Im pretty happy and not too fussed about the current share price as its a great opportunity to acquire. Just a shame you can't buy that many.
hutch_pod: Wow. Great to see GWP's news and share price reaction
minimarvel: Much speak of solar orders....but is not one of these huge orders from Hanergy China, that has since cancelled all orders due to fraud in the upper management. Does an order still exist? and if not why has this news of a cancelled order been released to shareholders. Enough news is made of potential orders but nothing in relation to the status of existing orders. Could make a huge difference to the share price?
timbo003: I'm surprised by the share price reaction to today's results, it all seems to be going to plan and there were quite a few things to like, these snippets caught my eye: Several studies have been published in recent months which reinforce the observation that there is a dysfunctional response to common respiratory viruses (mainly rhinovirus) in asthmatic patients, supporting the use of inhaled IFN-beta in asthma patients during cold and flu infections. Two of these studies identified possible causes. In the first study1, lung samples from asthmatic patients expressed more of the SOCS1 protein, which is known to supress IFN-beta production. This may explain the lower levels of IFN-beta observed in cells from asthmatic patients when they are exposed to the common cold virus. In a second study2, it was shown that corticosteroids (an essential anti-inflammatory asthma therapy) may be compromising the lung's antiviral defences, an unwanted effect that could be overcome through application of IFN-beta. These two papers further support the rationale for using inhaled AZD9412 to boost antiviral defences in asthmatic patients when they are infected with common cold viruses. Since licensing the programme, AstraZeneca has completed the preparatory work to enable the commencement of a Phase IIa clinical trial of AZD9412. The first patient was enrolled in the trial on 22 July 2015. .......It is expected to conclude in 2017. In the collaboration, Synairgen will work with Pharmaxis to identify the most suitable compound for the inhibition of LOXL2 in IPF. Synairgen will progress the compound into Phase I and potentially Phase II clinical trials. It is expected that Synairgen will have a 50:50 stake in the collaboration and of any resultant commercialisation by the end of Phase I, which is the earliest point that licensing to a large pharma partner is likely to occur. The compound may have utility beyond IPF in diseases such as Non-alcoholic Steatohepatitis (NASH) and cancer, which will be explored by Pharmaxis. Synairgen will have a minority stake in revenues generated for the IPF compound in diseases outside of IPF. In line with the strategy to bring new programmes into the Company for development and future potential licensing, we continue to assess opportunities using our BioBank technology platform. The first of these opportunities has been announced for the disease IPF in a collaboration with Pharmaxis, which is progressing well. We look forward to announcing other new programmes in the future as we continue to broaden our pipeline
timbo003: The Synairgen AGM was held at 11 a.m. on Monday 22 June 2015 at the offices of Fasken Martineau LLP, 17 Hanover Square, London W1S 1HU. Unfortunately there was loads of building work going on in Hanover Square, with pavements blocked off, so it took a while to navigate around the square and locate the building, so arrived a few minutes late. There were only three ordinary shareholders present (apparently that was two more than last year!) as well as the BOD and a few of the usual AGM functionaries. The Chairman kicked off the meeting with the formal resolutions, we then had around 15 minutes of formal Q&As and then another 30 minutes or so informal Q&As over coffee. The resolutions were all easily passed with no dissenters present in the room. There was no presentation and no new news given out, so the most recent relevant documents are the Annual Report and the March 2015 corporate presentation: Main highlights from the Q&As were as follows: SNG001 I questioned the BOD at length on the forthcoming AZ study and began by commenting that it seemed to be taking a long time to initiate, given that the deal was signed around 12 months ago. The response was that AZ wanted to do the study in the Northern hemisphere (more clinics, more asthmatics) and it should commence at the start of the cold season. When asked whether they thought there was any possibility that AZ were deliberately dragging their heels and had just acquired the rights to let the project wither on the vine (a tactic sometimes used by big pharma) the answer was an emphatic NO, they expanded by saying that the AZ staff working on the project appeared enthusiastic and committed. The study will use patients with more severe asthma (patients on step 4 and step 5 treatment, see figure below) From: Enrolled patients should experience an exacerbation triggered by an upper respiratory tract infection. I asked whether AZ had considered using an induced cold model, see news on retroscreen virology (recently renamed hVIVO): The BOD responded that induced models may not produce reliable and sufficiently severe infections suitable for this purpose. I asked whether there would be a further milestone payment following commencement of the study, the response was that there will not be for this first study as it was a confirmatory study, but for future studies, certain milestone payments would be payable, I asked whether a breakdown of the milestone payments was in the public domain, the answer was no, as they are restricted by the agreement with AZ. I then enquired about royalties payable to the University of Southampton for SNG001 and asked about the duration of the low single digit royalty payable to the Uni. I was told that there was a full disclosure in the Aim admission document, see link below (I haven’t had a chance to have a good look at it yet): I was pleasantly surprised to learn that the low single digit royalty that SNG will pay the Uni applies to income received by Synairgen from AZ, not the gross income received by AZ, in other words it really is just peanuts and that makes me far less concerned about the duration of the royalty arrangement. Biobank and new targets I asked about progress on the targets identified using the biobank and stated that there hadn’t been a meaningful update with new information since last autumn. I was told that they were still looking at around the same number of targets and they were busy on additional lab work, validation, securing IP where possible and finalising agreements with the owners of the molecules if applicable. They would not commit to any timings other than to restate that they hoped to have two candidates “clinic ready” by the time the SNG001 confirmatory study completes in 2017. I said that I hoped that the main candidates were to cover a range of several different target indications, rather than 5 new drug candidates for asthma. They assured me that they did, but wouldn’t expand further. That was the cue for me to mention the two recently filed UK patent applications which name Karus Therapeutics as co-inventor concerning Idopathic Pulmonary Fibrosis (see post #295 above). They seemed surprised (and possibly slightly concerned) that I had been able to dig them up so easily. I suggested in future they should give patent applications very generic titles, so not to give anything away (there were some nods of agreement among the BOD). Future Funding I enquired if and when future funding might take place. Their position is that they should have adequate funding at least up until the completion of the SNG001 study in 2017. If they wished to take one or more of the biobank screening candidates into the clinic themselves, then they would look to raise further funds. If they partnered the biobank candidates, future funding may not be necessary. I stated that should they raise new money via equity, could they please do all they can to give ordinary PIs the opportunity to invest on the same terms as the institutions and I reeled off some of the reasons why it was important (PIs determine the share price more than the institutions, PIs provide the liquidity etc), they didn’t disagree and seemed receptive to the suggestion. I also said that they should try to ensure that any open offer qualified for EIS tax reliefs, which can be of enormous benefit to PIs, even though it doesn’t affect most IIs. We then discussed the possibility that Synairgen may have difficulty qualifying for EIS in future if a new maximum 12 year restriction on company age is introduced in the next budget, as seems possible: We agreed that it would be disappointing if this restriction were to be introduced, but I repeated the request that PIs should ideally get a chance to invest on the same terms as IIs irrespective of whether EIS tax breaks were applicable, the BOD seemed to agree. Summary That probably more or less sums it up. I’m glad I went along, it certainly helped answer some of my more pressing questions. I came away with the impression that news on commencement of the SNG001 confirmatory study is fairly imminent (this autumn), but after then we might be a bit light on news for quite a while, although RM did say that we would try to arrange another investor road show in the Autumn, that would presumably be to coincide with the start of the SNG001 confirmatory clinical.
tomboyb: Up 12% - Griffiths bought BlinkX frome around 23-24p - As per share price it seems a good investment and time will always tell medium long term -
Synairgen share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170221 02:53:32